Home > Resources > Company Profiles > Sanofi-Aventis ADS

Sanofi-Aventis ADS (SNY)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

Gerard Le Fur , Director/CEO

www.sanofi-aventis.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A pharmaceutical group is engaged in the research, development, manufacture and marketing of healthcare products.

Portfolio Articles

Pharma's Fees
How the big drugmakers tend to your doctor.
Nov 19 2007
A Big Boost for Bristol
After

Jun 19 2007

See more news on this company

News Feeds

Zentiva rejects Sanofi Aventis bid AP
Jul 18 2008
Dollar, cost cuts help Novartis Q2 beat forecast Reuters
Jul 17 2008
Sanofi sees global vaccine sales doubling: report Reuters
Jun 26 2008
Groups to buy millions of vaccines for children AP
Jun 25 2008

Portfolio Blogs

A Black Eye for a Big Drugmaker
Sep 10 2007

Press Releases

Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes Jul-22-2008, 08:00AM EDT
EvaluatePharma's World Preview Report Finds European Companies Taking Top 4 Ranking Positions by 2012 Jul-22-2008, 06:01AM EDT
Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program Jun-26-2008, 08:52AM EDT
Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility to Respond to Soaring Demand Worldwide Jun-25-2008, 03:47PM EDT
U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) Jun-23-2008, 08:00AM EDT

Employees

Number of Employees: 99,495

Revenue per Employee: $394,390

Top Executives

Philippe Luscan, Vice President, Divisional

Hanspeter Spek, Divisional Executive VP

Jean- Michel Levy, Senior VP, Divisional

Laurence Debroux, CFO/Senior VP

Belen Garijo, Senior VP, Divisional

Gilles Lhernould, Divisional Senior VP

Jean-Claude Leroy, Executive VP, Divisional

Pierre Chancel, Senior VP, Divisional

Karen Linehan, General Counsel/Senior VP, Divisional

Jean-Philippe Santoni, Senior VP, Divisional

Philippe Peyre, Senior VP, Divisional

Jean-Claude Armbruster, Divisional Senior VP/Other Corporate Officer

Heinz-Werner Meier, Senior VP, Divisional

David Williams, Senior VP, Divisional

Gregory Irace, Senior VP, Divisional

Olivier Charmeil, Senior VP, Divisional

Philippe Fauchet, Senior VP, Divisional

Wayne Pisano, Senior VP, Divisional

Marie-Helene Laimay, Senior VP, Divisional

Timothy Rothwell, Other Corporate Officer

Michel Labie, Senior VP, Divisional

Marc Cluzel, Senior VP, Divisional

Antoine Ortoli, Senior VP, Divisional

Christian Lajoux, Senior VP, Divisional

Board of Directors

Jean- FranÃ§ois Dehecq, Chairman of the Board/Director

Thierry Desmarest, Director

Lord Douro, Director

Christian Mulliez, Director

Igor Landau, Director

Uwe Bicker, Director

Gunter Thielen, Director

Bruno Weymuller, Director

Jean-Rene Fourtou, Director

Claudie Haignere, Director

Lindsay Owen-Jones, Director

Jean-Marc Bruel, Director

Klaus Pohle, Director

Robert Castaigne, Director

Patrick de la Chevardiere, Director

Gerard Van Kemmel, Director

Financials

Quarterly

Annual

Income Statement	03/2008	08/2007	04/2007	09/2006
Sales	NA	NA	NA	1.89 Bil.
Gross Operating Profit	9.95 Bil.	9.43 Bil.	9.34 Bil.	7.62 Bil.
Operating Income before D & A (EBITDA)	9.95 Bil.	9.43 Bil.	9.34 Bil.	3.61 Bil.
Total Income Before Interest Expenses (EBIT)	9.95 Bil.	9.43 Bil.	9.34 Bil.	1.71 Bil.
Total Net Income	1.85 Bil.	1.78 Bil.	1.03 Bil.	1.11 Bil.
Basic EPS, Total	0.69	0.66	0.38	0.42
Diluted EPS, Total	0.69	0.65	0.38	0.4

BALANCE STATEMENT	03/2008	08/2007	04/2007	09/2006
Cash and Equivalents	NA	NA	NA	1.48 Bil.
Total Assets	NA	NA	NA	15.72 Bil.
Total Liabilities	NA	NA	NA	18.21 Bil.
Total Capitalization	NA	NA	NA	62.3 Bil.

Cash Flow	03/2008	08/2007	04/2007	09/2006
Net Cash From Continuing Operations	NA	NA	NA	3.79 Bil.
Net Cash From Investing Activities	NA	NA	NA	96 Mil.
Net Cash From Financing Activities	NA	NA	NA	-3.96 Bil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	-114 Mil.

Income Statement	2008	2007	2006	2005
Sales	9.58 Bil.	7.22 Bil.	6.69 Bil.	4.19 Bil.
Gross Operating Profit	33.07 Bil.	31.7 Bil.	27.06 Bil.	16.19 Bil.
Operating Income before D & A (EBITDA)	14.97 Bil.	15.27 Bil.	12.51 Bil.	-4 Mil.
Total Income Before Interest Expenses (EBIT)	9.78 Bil.	7.46 Bil.	4.26 Bil.	-3.79 Bil.
Total Net Income	7.69 Bil.	5.29 Bil.	2.67 Bil.	-4.89 Bil.
Basic EPS, Total	2.85	1.96	1	-2.65
Diluted EPS, Total	2.84	1.95	1	-2.65

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	2.5 Bil.	1.52 Bil.	1.48 Bil.	2.08 Bil.
Total Assets	18.33 Bil.	16.05 Bil.	15.53 Bil.	19.57 Bil.
Total Liabilities	14.12 Bil.	13.56 Bil.	18.25 Bil.	20.33 Bil.
Total Capitalization	70.5 Bil.	66.12 Bil.	60.82 Bil.	59.89 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	10.38 Bil.	8.72 Bil.	7.57 Bil.	5.46 Bil.
Net Cash From Investing Activities	-2.51 Bil.	-1.04 Bil.	-1.3 Bil.	-19.16 Bil.
Net Cash From Financing Activities	-7.04 Bil.	-7.73 Bil.	-7.08 Bil.	12.49 Bil.
Net Change in Cash & Cash Equivalents	815 Mil.	-127 Mil.	-699 Mil.	-1.24 Bil.

Sanofi-Aventis ADS (SNY)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request